 Nishank Jain
| Title | Associate Professor |
|---|
| Institution | University of Arkansas for Medical Sciences |
|---|
| Department | Internal Med, College of Medicine |
|---|
| Division | Internal Med Nephrology |
|---|
| Address | 324 UAMS Campus Dr.
Mail Slot # LR 111/D@VA
Little Rock AR 72205
|
|---|
| Phone | 501-686-5295 |
|---|
ORCID
.gif) | 0000-0001-6356-6579  |
|---|
| vCard | Download vCard |
|---|
|
|
|
 Overview Nishank Jain, MD, MPH, is a nephrologist and an Associate Professor in the Department of Medicine at University of Arkansas for Medical Sciences, Little Rock, AR. He completed his clinical and research fellowship at UT Southwestern Medical Center, Dallas, TX, before joining as a faculty member. His research interest is in the role of platelets in CKD pathophysiology and use of antiplatelet agents in patients with kidney diseases. He has been funded by post-doctoral fellowship grant from the American Heart Association (AHA), institutional KL2 grant and career development grants from the American Society of Nephrology and the AHA.
Dr. Jain is passionate about education and is driven by training and engaging medical students for a career in academic medicine. He has also helped medical students receive Honors in Research upon graduation. Dr. Jain has received medical student teaching awards. He has also engaged in SSCI activities by sending medical students to present original research work at the Annual Meetings.
Biography | 2013 | Fellow of American Society of Nephrology | | 2019 | Fellow of American Heart Association | | 2019 | Red Sash Award for teaching medical students, UAMS | | 2019 | ICARE award, Little Rock VA | | 2021 | Southern Society of Clinical Investigation, SSCI | | 2022 | Red Sash Award for teaching medical students, UAMS | | 2022 | Award of tenure, UAMS |
Research KL2TR003108 (John M Arthur)Jul 1, 2022 - Jun 30, 2024 NIH/NCATS
Platelet, Inflammation and Thrombosis in Chronic Kidney Disease
Role Description: We will describe an in-depth interactions between platelets and leukocytes in mouse models of platelet defect that is engineered to reduce interactions with leukocytes. This will help us determine if CKD is an exacerbating factor for inflammation in these mouse models.
Role: Principle Investigator |
| #2021-04 (JAIN, NISHANK)Jan 1, 2022 - Dec 31, 2024 Dialysis Clinic, Inc.
Platelet-Leukocyte Axis in Patients with Chronic Kidney Disease
Role: Principal Investigator |
| 2022-04 (JAIN, NISHANK)Jan 1, 2022 - Dec 31, 2024 Dialysis Clinic, Inc.
Platelet-Leukocyte Axis in Patients with Chronic Kidney Disease
Role: Principal Investigator |
| #2021 (JAIN, NISHANK)Jan 1, 2022 - Dec 31, 2023 Dialysis Clinic, Inc.
Platelet-Leukocyte Axis in Patients with Chronic Kidney Disease
Role: Principal Investigator |
| Hornick Endowment grant (Nishank Jain)Jan 1, 2021 - Dec 30, 2021 UAMS Office of Research
Study of uremic toxins and levels of antiplatelet therapy to investigate mechanisms of excessive stroke in patients with chronic kidney disease
Role Description: This grant acts as a supplement to the ongoing CKD-Platelet trial. We are measuring levels of antiplatelet drugs and uremic toxins using mass spectrometry; and, compare them between the CKD and the non-CKD groups. My goal is to investigate mechanisms of higher stroke rates in CKD patients vs. non-CKD controls despite receiving antiplatelet therapy.
Role: Principal Investigator |
| Data Scholar Award (Nishank Jain)Jul 1, 2020 - Jun 30, 2021 Translational Research Institute, UAMS
PREDICT-BLEED study
Role Description: This is an observational study of patients on chronic dialysis that are prescribed antiplatelet agents, specifically P2Y12 inhibitors. It used national registry of Medicare patients on chronic dialysis and investigated predictors of bleeding in this patient population who are prescribed antiplatelet drugs. We also explored predictors of recurrent bleeding events in subgroup analyses. As part of the program, I enrolled in a certificate course of healthcare analytics to utilize learned knowledge from the coursework in analyzing databases; hence, generate results related to antiplatelet drugs in CKD patient population. My personal goal is to generate enough knowledge that a multicenter human trial can be designed in an attempt to determine efficacy and safety of antiplatelet drugs in this vulnerable population- precisely those that are excluded systematically from landmark randomized clinical trials.
Role: Principal Investigator |
| Joseph V Bonventre Career Development grant (Nishank Jain)Jul 1, 2018 - Jun 30, 2021 American Society of Nephrology Foundation for Kidney Research
A Mechanistic Study in Patients with Non-Dialysis Chronic Kidney Disease to Investigate Altered Platelet Response to Antiplatelet Therapy (CKD-Platelet Study)
Role Description: This is a randomized, double blind, placebo controlled clinical trial designed to investigate whether ticagrelor has greater antiplatelet effects than clopidogrel in non-dialysis CKD and inhibits platelets as effectively as in non-CKD controls. We also want to explore the mechanisms underlying the poor response of CKD patients to oral P2Y12 inhibitors.
Role: Principal Investigator |
| 16SDG31000045 (JAIN, NISHANK)Jul 1, 2016 - Oct 23, 2019 American Heart Association
Effectiveness and safety of clopidogrel, prasugrel and ticagrelor in patients with end stage renal disease (ESCALATE)
Role: Principal Investigator |
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
Don't see publications published under other names? Login to add alternative names.
-
Corken AL, Ong V, Kore R, Ghanta SN, Karaduta O, Pathak R, Rose S, Porter C, Jain N. Platelets, inflammation, and purinergic receptors in chronic kidney disease. Kidney Int. 2024 Sep; 106(3):392-399. PMID: 38821448.
-
Rasu RS, Phadnis MA, Xavier C, Dai J, Hunt SL, Jain N. P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis. Kidney Int Rep. 2024 Jul; 9(7):2125-2133. PMID: 39081724.
-
Tarun T, Davis OM, Ghanta SN, Jain N. Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD]. Kidney Int Rep. 2024 Jun; 9(6):1936. PMID: 38899220.
-
Kore R, Jadvani D, Arthur JM, Jain N. Authors' Reply: Platelet Count, Platelet Volume and CKD. J Am Soc Nephrol. 2024 02 01; 35(2):250-251. PMID: 38300718.
-
Kumar A, Chidambaram V, Geetha HS, Majella MG, Bavineni M, Pona PK, Jain N, Sharalaya Z, Al'Aref SJ, Asnani A, Lau ES, Mehta JL. Renal Biomarkers in Heart?Failure: Systematic Review and Meta-Analysis. JACC Adv. 2024 Feb; 3(2):100765. PMID: 38939376.
-
Tarun T, Ghanta SN, Ong V, Kore R, Menon L, Kovesdy C, Mehta JL, Jain N. Updates on New Therapies for Patients with CKD. Kidney Int Rep. 2024 Jan; 9(1):16-28. PMID: 38312786.
-
Davis OM, Kore R, Moore A, Ware J, Mehta JL, Arthur JM, Lynch DR, Jain N. Platelet Count and Platelet Volume in Patients with CKD. J Am Soc Nephrol. 2023 11 01; 34(11):1772-1775. PMID: 37677933.
-
Jain N, Corken A, Arthur JM, Ware J, Arulprakash N, Dai J, Phadnis MA, Davis O, Rahmatallah Y, Mehta JL, Hedayati SS, Smyth S. Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease. Vascul Pharmacol. 2023 02; 148:107143. PMID: 36682595.
-
Corken A, Ware J, Dai J, Arthur JM, Smyth S, Davis CL, Liu J, Harville TO, Phadnis MA, Mehta JL, Rahmatallah Y, Jain N. Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study. Kidney360. 2022 12 29; 3(12):2036-2047. PMID: 36591354.
-
Jain N, Martin BC, Dai J, Phadnis MA, Al-Hindi L, Shireman TI, Hedayati SS, Rasu RS, Mehta JL. Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis. Kidney360. 2022 08 25; 3(8):1374-1383. PMID: 36176642.
-
Jain N, McAdams M, Hedayati SS. Screening for Cardiovascular Disease in CKD: PRO. Kidney360. 2022 11 24; 3(11):1831-1835. PMID: 36514398.
-
Jain N, Phadnis MA, Martin BC, Mehta JL. Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis. Am J Cardiol. 2022 01 01; 162:209-211. PMID: 34740395.
-
Jain N, Phadnis MA, Hunt SL, Dai J, Shireman TI, Davis CL, Mehta JL, Rasu RS, Hedayati SS. Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis. Kidney Int Rep. 2021 Sep; 6(9):2381-2391. PMID: 34514199.
-
Jain N, Corken AL, Kumar A, Davis CL, Ware J, Arthur JM. Role of Platelets in Chronic Kidney Disease. J Am Soc Nephrol. 2021 Jul; 32(7):1551-1558. PMID: 34140394.
-
Rasu RS, Hunt SL, Dai J, Cui H, Phadnis MA, Jain N. Accurate Medication Adherence Measurement Using Administrative Data for Frequently Hospitalized Patients. Hosp Pharm. 2021 Oct; 56(5):451-461. PMID: 34720145.
-
Jain N, Wan F, Kothari M, Adelodun A, Ware J, Sarode R, Hedayati SS. Association of platelet function with depression and its treatment with sertraline in patients with chronic kidney disease: analysis of a randomized trial. BMC Nephrol. 2019 10 29; 20(1):395. PMID: 31664940.
-
Jain N, Hunt SL, Cui H, Phadnis MA, Mahnken JD, Shireman TI, Dai J, Mehta JL, Rasu RS. Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis. Cardiovasc Drugs Ther. 2019 10; 33(5):511-521. PMID: 31729588.
-
Reilly RF, Jain N. Warfarin in nonvalvular atrial fibrillation-Time for a change? Semin Dial. 2019 11; 32(6):520-526. PMID: 31209952.
-
Gregg LP, Jain N, Carmody T, Minhajuddin AT, Rush AJ, Trivedi MH, Hedayati SS. Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes. Am J Nephrol. 2019; 50(1):37-47. PMID: 31167183.
-
Jain N, Reilly RF. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. Clin J Am Soc Nephrol. 2019 02 07; 14(2):278-287. PMID: 29802125.
-
Singh M, Raghavan D, Williams JS, Martin BC, Hudson TJ, Owen RR, Jain N. Prevalence of Chronic Kidney Disease, Thrombotic Cardiovascular Events, and Use of Oral P2Y12 Inhibitors among Veterans. Am J Nephrol. 2018; 47(2):67-71. PMID: 29393120.
-
Hedayati SS, Gregg LP, Carmody T, Jain N, Toups M, Rush AJ, Toto RD, Trivedi MH. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. JAMA. 2017 11 21; 318(19):1876-1890. PMID: 29101402.
-
Gregg LP, Adams-Huet B, Li X, Colbert G, Jain N, de Lemos JA, Hedayati SS. Effect Modification of Chronic Kidney Disease on the Association of Circulating and Imaging Cardiac Biomarkers With Outcomes. J Am Heart Assoc. 2017 Jul 05; 6(7). PMID: 28679558.
-
Jain N, Reilly RF. Hungry bone syndrome. Curr Opin Nephrol Hypertens. 2017 07; 26(4):250-255. PMID: 28375869.
-
Jain N, Carmody T, Minhajuddin AT, Toups M, Trivedi MH, Rush AJ, Hedayati SS. Prognostic Utility of a Self-Reported Depression Questionnaire versus Clinician-Based Assessment on Renal Outcomes. Am J Nephrol. 2016; 44(3):234-44. PMID: 27592294.
-
Jain N, Reilly RF. Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current?Knowledge and Future Directions. Semin Dial. 2016 09; 29(5):374-81. PMID: 27061079.
-
Jain N, Li X, Adams-Huet B, Sarode R, Toto RD, Banerjee S, Hedayati SS. Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease. Am J Cardiol. 2016 Feb 15; 117(4):656-663. PMID: 26725101.
-
Colbert G, Jain N, de Lemos JA, Hedayati SS. Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD. Clin J Am Soc Nephrol. 2015 Mar 06; 10(3):515-29. PMID: 25403922.
-
Jain N, Reilly RF. Effects of dietary interventions on incidence and progression of CKD. Nat Rev Nephrol. 2014 Dec; 10(12):712-24. PMID: 25331786.
-
Jain N, Reilly RF. Are calcium-based phosphate binders ever preferable in dialysis patients? Semin Dial. 2014 May-Jun; 27(3):269-72. PMID: 24620781.
-
Jain N, Minhajuddin AT, Neeland IJ, Elsayed EF, Vega GL, Hedayati SS. Association of urinary sodium-to-potassium ratio with obesity in a multiethnic cohort. Am J Clin Nutr. 2014 May; 99(5):992-8. PMID: 24552753.
-
Jain N, Elsayed EF. Dietary phosphate: what do we know about its toxicity. J Nephrol. 2013 Sep-Oct; 26(5):856-64. PMID: 23475467.
-
Jain N, Trivedi MH, Rush AJ, Carmody T, Kurian B, Toto RD, Sarode R, Hedayati SS. Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). Contemp Clin Trials. 2013 Jan; 34(1):136-44. PMID: 23085503.
-
Jain N, Hedayati SS, Sarode R, Banerjee S, Reilly RF. Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence? Clin J Am Soc Nephrol. 2013 Apr; 8(4):665-74. PMID: 23024160.
-
Jain N, Reilly RF. Risk factors: filling in the gap. Nat Rev Nephrol. 2012 Oct; 8(10):562-3. PMID: 22890182.
-
Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, Banerjee S. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012 May 15; 109(10):1510-3. PMID: 22342847.
-
Jain N, Hedayati SS. How should clinicians interpret cardiac troponin values in patients with ESRD? Semin Dial. 2011 Jul-Aug; 24(4):398-400. PMID: 21851399.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
| Year | Publications |
|---|
| 2011 | 1 | | 2012 | 4 | | 2013 | 1 | | 2014 | 4 | | 2015 | 1 | | 2016 | 2 | | 2017 | 3 | | 2018 | 2 | | 2019 | 4 | | 2020 | 1 | | 2021 | 3 | | 2022 | 3 | | 2023 | 3 | | 2024 | 5 |
To return to the timeline, click here.
|
Jain's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|